Search

A closer look at the new wave of glaucoma surgery – radical or old school?

Glaucoma is a challenging condition to treat because the exact pathophysiology remains unclear and the only readily modifiable factor is the intraocular pressure (IOP). Additionally, most glaucoma patients are completely asymptomatic, yet are often subjected to lifelong medical therapy. The...

Optimising the ocular surface by managing meibomian gland dysfunction

Meibomian gland dysfunction (MGD) is ubiquitous. Ocular surface inflammation and irritation are prevalent in most ophthalmology clinics: corneal, cataract, glaucoma, oculoplastic, paediatric, vitreo-retinal, medical retina and refractive surgery. These patients also represent roughly one third of those attending for emergency...

An introduction to research governance

Research is the process of acquiring new generalisable knowledge and should be fully integrated into health care work. There is a growing drive to encourage and further develop evidence-based practice in ophthalmology so that staff and patients benefit from improved...

What’s new in glaucoma? Clinical trials drive practice changes, surgical advancements gather pace

Rod McNeil reviews the latest developments in the treatment of glaucoma in the UK. Primary open-angle glaucoma (POAG), which accounts for over two-thirds of all glaucoma cases, has an estimated UK prevalence in 2017 of approximately 2% of people over...

An update on idiopathic intracranial hypertension

The incidence of Idiopathic intracranial hypertension (IIH) is increasing, likely in line with the worldwide epidemic of obesity. To date, there have been revisions in the terminology used and diagnostic criteria for IIH; these recognise the need to exclude secondary...